Company news
Neuroscientific Biopharmaceuticals Ltd. news in 2022
Neuroscientific Biopharmaceuticals Ltd.'s news releases, calls and decks from 2022, newest first.
NSB files new patent
December 4, 2022
Appointment of Interim CEO
November 22, 2022
Investor Update Presentation
September 20, 2022
CEO Resignation
September 9, 2022
HREC decision to not approve Phase I Clinical Trial
September 6, 2022
2022 Annual Report and Appendix 4E
August 29, 2022
NeuroScientific releases FY2022 Results
August 29, 2022
HREC Submission for Phase I Clinical Trial
July 12, 2022
First Subject Recruited for Early-Phase Clinical Trial
June 30, 2022
Positive results in MS animal study
June 14, 2022
Ethics Approval Granted for Early-Phase Clinical Trial
June 7, 2022
HREC Submission for early-phase Clinical Trial
May 10, 2022
Positive safety result supports advance to clinical trials
April 13, 2022
New data demonstrates EmtinB activity in autoimmune diseases
March 10, 2022
NSB 1HY22 Key Activity Highlights
February 27, 2022
Successful completion of key studies in lead up to Phase I
February 7, 2022
Decks in 2022
- Shareholder Meeting (November 2022)
Shareholder meeting · 13 slides · Nov 24, 2022
- Corporate Update (September 2022)
Corporate update · 8 slides · Sep 20, 2022
- Gold Coast Investment Showcase 2022
Conference · 16 slides · Jun 22, 2022
- Investor Presentation (March 2022)
Investor deck · 13 slides · Mar 24, 2022